Important Class Action Notice for Cassava Sciences Investors
Attention to all investors involved with Cassava Sciences, Inc. (NASDAQ: SAVA) - a class action lawsuit is currently underway that requires immediate attention. Investors who incurred losses exceeding $100,000 during the designated class period are encouraged to act now to protect their rights and explore possible recoveries. This message comes from Kahn Swick & Foti, LLC, a respected law firm specializing in securities litigation.
Understanding the Class Action Lawsuit
If you are a shareholder of Cassava and purchased securities between February 7, 2024, and November 24, 2024, you are eligible to participate in this lawsuit. The case is being heard in the United States District Court for the Western District of Texas, and the deadline to apply as a lead plaintiff is approaching rapidly.
What Actions to Take
You may reach out to KSF’s Managing Partner Lewis Kahn at 1-877-515-1850 to discuss your legal rights. It is crucial for impacted investors to understand their avenues for recovering any financial losses and what the lawsuit entails.
Key Dates and Deadlines
All claims must be submitted no later than the set deadline of February 10, 2025. This date marks an essential step forward for those who wish to ensure their voices are heard through the legal process. Applications for lead plaintiff positions should be meticulously prepared and submitted to the court by the deadline.
Allegations Against Cassava
Cassava Sciences and certain executives have been accused of failing to disclose significant material information throughout the class period, which is a violation of federal securities laws. This lack of transparency ultimately resulted in major financial ramifications for investors.
Impact of Recent Company Disclosure
The situation escalated when Cassava announced the findings of their Phase 3 study for simufilam, aimed at treating Alzheimer's disease. Results revealed that the treatment did not meet its intended endpoints, leading to a sharp decline in share prices. From a closing price of $26.48 on November 22, 2024, shares plummeted to just $4.30 following this revelation. Such a dramatic loss highlights the risks involved and emphasizes the importance of stakeholders understanding their rights.
About Kahn Swick & Foti, LLC
KSF, led by Charles C. Foti, Jr., a former Attorney General of Louisiana, is well-regarded in representing clients in securities litigation. Their expertise encompasses a wide array of investors, ranging from retail investors to large institutional clients, all facing challenges due to corporate fraud or misconduct.
Learn More About KSF
For those interested in learning more about KSF and its services, their website offers a wealth of information. Engaging with experienced legal counsel can provide the necessary support and guidance needed during these turbulent times in the market.
Frequently Asked Questions
What should I do if I invested in Cassava Sciences during the specified period?
If you purchased shares between February 7, 2024, and November 24, 2024, you should contact KSF to understand your options for joining the class action lawsuit.
How do I apply to be a lead plaintiff?
Interested investors must submit their application to the court by February 10, 2025, to be considered for the lead plaintiff position in the class action.
What are the risks of not participating in the lawsuit?
Failing to participate may limit your chances of recovering losses incurred from your investments in Cassava Sciences.
What kind of compensation can I expect?
The potential compensation can vary significantly depending on the case's outcome, but it aims to recover economic losses due to the alleged misconduct.
Who can I contact for more details?
You can reach out to KSF’s team directly for any questions or clarification regarding your rights as an investor or the lawsuit's proceedings.
